Full Breakdown
TrumpRx Pricing Claim Tested: Mixed Results in International Comparison
By Drooid · · How we work
Core Event – Trump’s “Lowest-Price Anywhere” Claim Scrutinized
The Kaiser Family Foundation (KFF) examined 32 brand-name drugs without generic equivalents sold through TrumpRx and compared their U.S. list prices with public prices in 11 wealthy countries. The analysis found 17 drugs cheaper than the foreign average and 15 more expensive. Only five were the cheapest worldwide, while thirteen were the most expensive. Notable gaps included Ozempic at $349/month in the U.S. versus $190 abroad, Enbrel at $3,354/month versus a $641 foreign average, and Rydapt at $2,909 for 56 capsules versus $5,901 in France.
Background & Context
TrumpRx launched in February with a few dozen brand-name drugs and now lists over 800 medications. The White House says discounts come from “most-favored-nation” agreements, where manufacturers charge Americans the lower prices they offer other countries in exchange for tariff relief. The program uses GoodRx pricing data and blends existing manufacturer discounts with newly negotiated terms, though the contracts remain confidential. Unlike President Biden’s Medicare-negotiated pricing, TrumpRx relies on voluntary agreements and directs consumers to coupon programs that do not count toward insurance costs.
Data & Statistics
| Metric | Figure |
|---|---|
| Drugs listed on TrumpRx (late August) | >800 |
| Brand-name drugs without generic equivalents | 79 |
| Drugs with foreign price data used in KFF analysis | 32 |
| Drugs cheaper than foreign average | 17 |
| Drugs more expensive than foreign average | 15 |
| Drugs cheapest worldwide | 5 |
| Drugs most expensive worldwide | 13 |
| Ozempic (U.S.) | $349/month |
| Ozempic (next-highest foreign) | $190/month |
| Enbrel (U.S.) | $3,354/month |
| Enbrel (foreign average) | $641/month |
| Rydapt (U.S.) | $2,909 for 56 capsules |
| Rydapt (France) | $5,901 for 56 capsules |
Official Statements & Responses
- White House officials described the discounts as stemming from “most-favored-nation” deals but declined to release the contracts.
- KFF deputy director Juliette Cubanski called the picture “a mixed bag,” noting genuine savings on some drugs and higher prices on others.
- Dr. Benjamin Rome, Harvard Medical School researcher, said the findings were unsurprising given the program’s limited scope.
Verbatim Quotes
- “It's kind of a mixed bag,” — Juliette Cubanski, KFF
- “But those generics and the low prices for those generics pre-existed the TrumpRx website,” — Juliette Cubanski, KFF
Conflicting Reports & Gaps
- Scope of Comparison – KFF analyzed 32 drugs while TrumpRx lists more than 800; the unexamined majority could shift the assessment.
- Price Basis – Retail list prices were converted to U.S. dollars without adjusting for cost-of-living or insurance structures, limiting comparability.
- Confidential Agreements – The terms of the “most-favored-nation” deals are not public, preventing verification.
- Domestic Baseline – KFF did not compare TrumpRx prices with what Americans pay through insurance or other U.S. channels, leaving net consumer impact unclear.
What’s Next
The administration continues negotiating additional “most-favored-nation” agreements, and KFF notes future analyses could differ if drugmakers raise prices abroad in response to U.S. deals. Ongoing monitoring will determine whether TrumpRx ultimately lowers U.S. drug costs relative to international benchmarks.